[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 39 of about 39
1. Abromowitch M, Sposto R, Perkins S, Zwick D, Siegel S, Finlay J, Cairo MS, Children's Oncology Group: Shortened intensified multi-agent chemotherapy and non-cross resistant maintenance therapy for advanced lymphoblastic lymphoma in children and adolescents: report from the Children's Oncology Group. Br J Haematol; 2008 Oct;143(2):261-7
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Shortened intensified multi-agent chemotherapy and non-cross resistant maintenance therapy for advanced lymphoblastic lymphoma in children and adolescents: report from the Children's Oncology Group.
  • Pediatric lymphoblastic lymphoma (LL) has utilized treatment strategies similar to childhood acute lymphoblastic leukaemia (ALL) with prolonged maintenance chemotherapy.
  • We report the results of a pilot study to estimate the feasibility, toxicity and efficacy of a 12-month aggressive multi-agent chemotherapy regimen in children and adolescents with advanced LL.
  • Patients achieving a complete response following induction and consolidation received six cycles of maintenance chemotherapy for a total duration of 12 months.
  • These results suggest that this experimental approach is safe and results in similar outcomes as more prolonged childhood ALL regimens.

  • Genetic Alliance. consumer health - Lymphoblastic lymphoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 2000 Jan 15;95(2):416-21 [10627444.001]
  • [Cites] Eur J Cancer. 2008 Apr;44(6):840-6 [18342502.001]
  • [Cites] Semin Hematol. 2003 Oct;40(4):274-80 [14582078.001]
  • [Cites] N Engl J Med. 1983 Mar 10;308(10):559-65 [6338381.001]
  • [Cites] J Clin Oncol. 1983 Sep;1(9):537-41 [6689428.001]
  • [Cites] Br J Cancer. 1984 Oct;50(4):457-62 [6333247.001]
  • [Cites] Blood. 1985 Nov;66(5):1110-4 [3840395.001]
  • [Cites] J Clin Oncol. 1986 May;4(5):744-52 [3517244.001]
  • [Cites] Med Pediatr Oncol. 1992;20(2):105-13 [1734214.001]
  • [Cites] Br J Haematol. 1992 Oct;82(2):310-6 [1419812.001]
  • [Cites] J Clin Oncol. 1993 Jun;11(6):1024-32 [8501488.001]
  • [Cites] J Clin Oncol. 1995 Jun;13(6):1368-76 [7751881.001]
  • [Cites] Pediatr Blood Cancer. 2005 Nov;45(6):753-69 [15929129.001]
  • [Cites] J Clin Oncol. 2006 Jan 20;24(3):491-9 [16421426.001]
  • [Cites] Pediatr Blood Cancer. 2006 Aug;47(2):130-40 [16358311.001]
  • [Cites] Cancer. 2003 Sep 15;98(6):1283-91 [12973853.001]
  • (PMID = 18759768.001).
  • [ISSN] 1365-2141
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / U10 CA098543; None / None / / U10 CA098543-08; United States / NCI NIH HHS / CA / CA98543; United States / NCI NIH HHS / CA / U10 CA098543-08
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] England
  • [Other-IDs] NLM/ NIHMS107033; NLM/ PMC3057023
  •  go-up   go-down


2. Mora J, Filippa DA, Qin J, Wollner N: Lymphoblastic lymphoma of childhood and the LSA2-L2 protocol: the 30-year experience at Memorial-Sloan-Kettering Cancer Center. Cancer; 2003 Sep 15;98(6):1283-91
Hazardous Substances Data Bank. METHOTREXATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lymphoblastic lymphoma of childhood and the LSA2-L2 protocol: the 30-year experience at Memorial-Sloan-Kettering Cancer Center.
  • BACKGROUND: Until the 1970s, diffuse lymphoblastic lymphoma (DLBL) was considered incurable.
  • Radiation therapy initially was administered to all patients with bulky disease in the primary tumor site.
  • Until 1977, the dose of radiation was 20-55 grays (Gy); from 1977 to 1989, the dose was 20 Gy.
  • After the fifth year of completion of treatment, all patients were evaluated comprehensively every 2 years.
  • Seventeen patients developed a disease recurrence and 15 died of disease.
  • Six patients developed secondary malignancies, four of whom died.
  • CONCLUSIONS: Long-term EFS can be achieved in the majority of patients with widely disseminated pediatric DLBL.
  • Chemotherapy alone appears to be sufficient prophylaxis against disease recurrence in the central nervous system.
  • No disease-related or treatment-related deaths were reported to occur > 4.5 years after diagnosis in the current study.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cyclophosphamide / therapeutic use. Daunorubicin / therapeutic use. Methotrexate / therapeutic use. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Prednisone / therapeutic use. Vincristine / therapeutic use
  • [MeSH-minor] Adolescent. Child. Child, Preschool. Disease-Free Survival. Female. Follow-Up Studies. Humans. Lymphoma, Non-Hodgkin / drug therapy. Male. Neoplasm Staging. Prognosis. Radiotherapy Dosage. Survival Rate. Treatment Outcome

  • Genetic Alliance. consumer health - Childhood Cancer.
  • Genetic Alliance. consumer health - Lymphoblastic lymphoma.
  • MedlinePlus Health Information. consumer health - Steroids.
  • Hazardous Substances Data Bank. DAUNORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2003 American Cancer Society.DOI 10.1002/cncr.11615
  • (PMID = 12973853.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; YL5FZ2Y5U1 / Methotrexate; ZS7284E0ZP / Daunorubicin; LSA2-L2 protocol
  •  go-up   go-down


3. Reiter A, Schrappe M, Ludwig WD, Tiemann M, Parwaresch R, Zimmermann M, Schirg E, Henze G, Schellong G, Gadner H, Riehm H: Intensive ALL-type therapy without local radiotherapy provides a 90% event-free survival for children with T-cell lymphoblastic lymphoma: a BFM group report. Blood; 2000 Jan 15;95(2):416-21
Hazardous Substances Data Bank. METHOTREXATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intensive ALL-type therapy without local radiotherapy provides a 90% event-free survival for children with T-cell lymphoblastic lymphoma: a BFM group report.
  • The purpose of our study was to investigate the efficacy of an acute lymphoblastic leukemia (ALL)-type treatment with moderate-dose, prophylactic cranial irradiation and without local radiotherapy for childhood T-cell lymphoblastic lymphoma (T-LBL).
  • From April 1990 to March 1995, 105 evaluable patients, 1.1 to 16.4 years of age, with T-LBL were enrolled in study NHL-BFM 90 (non-Hodgkin's lymphoma-Berlin-Frankfurt-Munster 90).
  • They received an 8-drug induction over 9 weeks followed by an 8-week consolidation including methotrexate (MTX) 5 g/m(2) x 4.
  • Patients with stage I (n = 2) and II (n = 2) continued with maintenance therapy (6-mercaptopurine daily and MTX weekly, both orally) until a total therapy duration of 24 months.
  • Patients with stage III (n = 82) and IV (n = 19) received an 8-drug intensification over 7 weeks and cranial radiotherapy (12 Gy for prophylaxis) after consolidation, followed by maintenance.
  • Patients received intensified chemotherapy if tumor regression on day 33 of induction was less than 70% or when vital residual tumor was present after the complete induction phase.
  • Two patients received intensified therapy due to less than 70% tumor regression on day 33.
  • We conclude that, with intensive ALL-type chemotherapy including moderate cumulative doses of anthracyclines 240 mg/m(2) and cyclophosphamide (3 g/m(2)) and moderate-dose prophylactic cranial irradiation but no local radiotherapy, an event-free survival rate of 90% can be achieved in childhood T-LBL. (Blood.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cranial Irradiation. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / radiotherapy
  • [MeSH-minor] 6-Mercaptopurine / administration & dosage. Adolescent. Child. Child, Preschool. Disease-Free Survival. Female. Humans. Infant. Male. Methotrexate / administration & dosage. Neoplasm Staging. Probability. Remission Induction. Time Factors

  • Genetic Alliance. consumer health - Lymphoblastic lymphoma.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. MERCAPTOPURINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10627444.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Multicenter Study
  • [Publication-country] UNITED STATES
  • [Chemical-registry-number] E7WED276I5 / 6-Mercaptopurine; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


Advertisement
4. Bay A, Oner AF, Etlik O, Yilmaz C, Caksen H: Myelopathy due to intrathecal chemotherapy: report of six cases. J Pediatr Hematol Oncol; 2005 May;27(5):270-2
Hazardous Substances Data Bank. METHOTREXATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Myelopathy due to intrathecal chemotherapy: report of six cases.
  • Intrathecal chemotherapy and systemic chemotherapy are used for both prophylaxis and treatment of central nervous system disease in hematologic malignancies.
  • However, intrathecal treatment has some adverse effects, such as arachnoiditis, progressive myelopathy, and leukoencephalopathy.
  • The authors describe six children in whom myelopathy and adhesive arachnoiditis developed after administration of intrathecal chemotherapy including methotrexate, cytosine arabinoside, and prednisolone.
  • Urinary retention and incontinence, the main presenting complaints in all patients, developed within 12 hours after intrathecal therapy and spontaneously resolved within 7 days.
  • Intrathecal chemotherapy, especially methotrexate, can cause spinal cord dysfunction in children with acute lymphoblastic leukemia and non-Hodgkin's lymphoma.
  • Arachnoiditis should be kept in mind as a causative factor in recurrent urinary tract infection in patients receiving intrathecal chemotherapy.
  • [MeSH-major] Central Nervous System Neoplasms / drug therapy. Folic Acid Antagonists / adverse effects. Injections, Spinal / adverse effects. Lymphoma, Non-Hodgkin / drug therapy. Methotrexate / adverse effects. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Spinal Cord Diseases / chemically induced

  • MedlinePlus Health Information. consumer health - Spinal Cord Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Pediatr Hematol Oncol. 2005 Jul;27(7):349-50 [16012322.001]
  • (PMID = 15891563.001).
  • [ISSN] 1077-4114
  • [Journal-full-title] Journal of pediatric hematology/oncology
  • [ISO-abbreviation] J. Pediatr. Hematol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Folic Acid Antagonists; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


5. Sandlund JT, Pui CH, Zhou Y, Behm FG, Onciu M, Razzouk BI, Hijiya N, Campana D, Hudson MM, Ribeiro RC: Effective treatment of advanced-stage childhood lymphoblastic lymphoma without prophylactic cranial irradiation: results of St Jude NHL13 study. Leukemia; 2009 Jun;23(6):1127-30
Hazardous Substances Data Bank. METHOTREXATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effective treatment of advanced-stage childhood lymphoblastic lymphoma without prophylactic cranial irradiation: results of St Jude NHL13 study.
  • There has been a steady improvement in cure rates for children with advanced-stage lymphoblastic non-Hodgkin's lymphoma.
  • To further improve cure rates whereas minimizing long-term toxicity, we designed a protocol (NHL13) based on a regimen for childhood T-cell acute lymphoblastic leukemia, which features intensive intrathecal chemotherapy for central -nervous system-directed therapy and excludes prophylactic cranial irradiation.
  • From 1992 to 2002, 41 patients with advanced-stage lymphoblastic lymphoma were enrolled on the protocol.
  • Thirty-three cases had a precursor T-cell immunophenotype, five had precursor B-cell immunophenotype and in three immunophenotype was not determined.
  • The treatment described here produces high cure rates in children with lymphoblastic lymphoma without the use of prophylactic cranial irradiation.

  • Genetic Alliance. consumer health - Lymphoblastic lymphoma.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. DAUNORUBICIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. MERCAPTOPURINE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 2003 Apr 1;21(7):1340-6 [12663724.001]
  • [Cites] Rev Clin Exp Hematol. 2002 Jun;6(2):161-80; discussion 200-2 [12196214.001]
  • [Cites] Blood. 2002 Jul 1;100(1):52-8 [12070008.001]
  • [Cites] Blood. 2002 Jul 1;100(1):43-7 [12070006.001]
  • [Cites] Leukemia. 2000 Dec;14(12):2286-94 [11187920.001]
  • [Cites] Blood. 2000 Jan 15;95(2):416-21 [10627444.001]
  • [Cites] J Clin Oncol. 2003 Oct 1;21(19):3616-22 [14512392.001]
  • [Cites] J Clin Oncol. 2006 Jan 20;24(3):491-9 [16421426.001]
  • [Cites] Leukemia. 1999 Mar;13(3):335-42 [10086723.001]
  • [Cites] Lancet. 1998 Feb 21;351(9102):550-4 [9492773.001]
  • [Cites] Cancer. 1997 Nov 1;80(9):1717-26 [9351539.001]
  • [Cites] N Engl J Med. 1996 May 9;334(19):1238-48 [8606720.001]
  • [Cites] J Clin Oncol. 1995 Jun;13(6):1368-76 [7751881.001]
  • [Cites] J Clin Oncol. 1993 Jun;11(6):1024-32 [8501488.001]
  • [Cites] Med Pediatr Oncol. 1992;20(2):105-13 [1734214.001]
  • [Cites] Med Pediatr Oncol. 1990;18(4):273-9 [2355886.001]
  • [Cites] Blood. 1985 Nov;66(5):1110-4 [3840395.001]
  • [Cites] J Clin Oncol. 1983 Sep;1(9):537-41 [6689428.001]
  • [Cites] Cancer. 1982 May 15;49(10):2112-35 [6896167.001]
  • [Cites] Semin Oncol. 1980 Sep;7(3):332-9 [7414342.001]
  • [Cites] Cancer. 1980 Feb 15;45(4):630-7 [6986967.001]
  • (PMID = 19194463.001).
  • [ISSN] 1476-5551
  • [Journal-full-title] Leukemia
  • [ISO-abbreviation] Leukemia
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P30 CA021765; None / None / / P30 CA021765-31; United States / NCI NIH HHS / CA / CA 21765; United States / NCI NIH HHS / CA / P30 CA021765-31
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 04079A1RDZ / Cytarabine; 5J49Q6B70F / Vincristine; 6PLQ3CP4P3 / Etoposide; 7S5I7G3JQL / Dexamethasone; 8N3DW7272P / Cyclophosphamide; E7WED276I5 / 6-Mercaptopurine; EC 3.5.1.1 / Asparaginase; VB0R961HZT / Prednisone; YL5FZ2Y5U1 / Methotrexate; ZS7284E0ZP / Daunorubicin
  • [Other-IDs] NLM/ NIHMS161582; NLM/ PMC2843413
  •  go-up   go-down


6. Gokhale CD, Udipi SA, Ambaye RY, Pai SK, Advani SH: Post-therapy profile of serum total cholesterol, retinol and zinc in pediatric acute lymphoblastic leukemia and non-Hodgkin's lymphoma. J Am Coll Nutr; 2007 Feb;26(1):49-56
Hazardous Substances Data Bank. ZINC, ELEMENTAL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Post-therapy profile of serum total cholesterol, retinol and zinc in pediatric acute lymphoblastic leukemia and non-Hodgkin's lymphoma.
  • OBJECTIVE: To assess serum albumin, total cholesterol, retinol, zinc and hemoglobin in children who had completed treatment for acute lymphoblastic leukemia (ALL) and Non-Hodgkin's lymphoma (NHL).
  • METHODS: The above parameters were analyzed in 105 ALL and NHL and 108 age and sex-matched controls.
  • Comparisons were made to stage of treatment (maintenance 6 with post-therapy), type of treatment (chemotherapy and radiation with only chemotherapy) and type of malignancy (ALL with NHL).
  • RESULTS: Only serum albumin in patients included at Maintenance(6) was significantly higher (t = 2.31, p = 0.05) than post-therapy patients.
  • No significant difference in serum values was observed by type of treatment.
  • Only total cholesterol was significantly higher in NHL patients than in ALL patients (t = 1.954, p = 0.05).
  • CONCLUSION: The results of the present study indicate that cancer and its treatment did not have any long-lasting effect on serum albumin, total cholesterol, retinol, zinc and hemoglobin.
  • A higher percentage of patients with low serum retinol levels may also be attributed to the possibility of urinary losses of retinol that occur during episodes of infection while on immunosuppressive anti-cancer drug therapy.
  • [MeSH-major] Lymphoma, Non-Hodgkin / blood. Nutritional Status. Precursor Cell Lymphoblastic Leukemia-Lymphoma / blood. Trace Elements / blood. Vitamin A / blood. Vitamins / blood


7. Chauhan A, Weiss J, Warrier R: Effective management of pain in pediatric hematology and oncology. Asian Pac J Cancer Prev; 2010;11(2):577-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effective management of pain in pediatric hematology and oncology.
  • In the last several decades, there have been major advances in the treatment of pediatric cancers.
  • 5 year survival of children with acute lymphoblastic leukemia has increased from 25% to 80%.
  • Early stages of non -Hodgkin's, Hodgkin's and Wilms tumors all have more than 90% long term survival.
  • Pain due to disease burden responds dramatically to chemotherapy and the uninitiated are often surprised by the sudden increase in activity and playfulness of children undergoing induction chemotherapy.
  • [MeSH-major] Hodgkin Disease / complications. Kidney Neoplasms / complications. Lymphoma, Non-Hodgkin / complications. Pain / drug therapy. Pain / etiology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / complications. Wilms Tumor / complications

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • MedlinePlus Health Information. consumer health - Pain.
  • MedlinePlus Health Information. consumer health - Wilms Tumor.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20843157.001).
  • [ISSN] 2476-762X
  • [Journal-full-title] Asian Pacific journal of cancer prevention : APJCP
  • [ISO-abbreviation] Asian Pac. J. Cancer Prev.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Thailand
  •  go-up   go-down


8. Gore L, Trippett TM: Emerging non-transplant-based strategies in treating pediatric non-Hodgkin's lymphoma. Curr Hematol Malig Rep; 2010 Oct;5(4):177-84
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Emerging non-transplant-based strategies in treating pediatric non-Hodgkin's lymphoma.
  • The non-Hodgkin's lymphomas comprise a heterogeneous group of tumors, with distinct clinical and pathologic features.
  • Although intensive multi-agent chemotherapy has made non-Hodgkin's lymphoma one of the most curable malignancies in children and young adults, there is room for improvement in treatment, particularly for those with advanced-stage disease and those who relapse after conventional therapy.
  • New approaches are now attempting to reduce the burden of treatment, to focus on novel and more specific biologic targets, and to improve outcomes for patients with advanced-stage disease while reducing the potential for late effects.
  • A comprehensive review of all potential agents is beyond the scope of this review, which will focus on some of the newer strategies for treating non-Hodgkin's lymphoma that are coming into clinical use today.
  • [MeSH-major] Lymphoma, Non-Hodgkin / therapy
  • [MeSH-minor] Adolescent. Antibodies, Monoclonal / immunology. Antibodies, Monoclonal / therapeutic use. Burkitt Lymphoma / pathology. Burkitt Lymphoma / therapy. Child. Cysteine Proteinase Inhibitors / therapeutic use. Histone Deacetylase Inhibitors / therapeutic use. Humans. Lymphoma, Large B-Cell, Diffuse / pathology. Lymphoma, Large B-Cell, Diffuse / therapy. Lymphoma, Large-Cell, Anaplastic / pathology. Lymphoma, Large-Cell, Anaplastic / therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / pathology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy. Protein Kinase Inhibitors / therapeutic use. Purine-Nucleoside Phosphorylase / antagonists & inhibitors. TNF-Related Apoptosis-Inducing Ligand / antagonists & inhibitors

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Pediatr Surg. 1992 Feb;27(2):230-5 [1564623.001]
  • [Cites] J Clin Oncol. 1989 Jan;7(1):92-9 [2642543.001]
  • [Cites] Blood. 2003 Dec 1;102(12):3871-9 [12933571.001]
  • [Cites] Cancer Res. 2000 Jan 15;60(2):383-9 [10667591.001]
  • [Cites] Mol Imaging Biol. 2004 Nov-Dec;6(6):411-6 [15564152.001]
  • [Cites] Pediatr Dev Pathol. 2005 Jan-Feb;8(1):52-60 [15719203.001]
  • [Cites] Blood. 2000 Jan 15;95(2):416-21 [10627444.001]
  • [Cites] Blood. 1996 Jan 15;87(2):423-38 [8555463.001]
  • [Cites] Blood. 1999 Jul 15;94(2):429-33 [10397709.001]
  • [Cites] Ann Oncol. 2000 Jan;11(1):53-8 [10690387.001]
  • [Cites] Br J Cancer. 2005 Apr 25;92(8):1430-41 [15846298.001]
  • [Cites] Eur J Nucl Med Mol Imaging. 2005 Jan;32(1):31-8 [15605288.001]
  • [Cites] Med Pediatr Oncol. 1975;1(3):235-63 [1232532.001]
  • [Cites] Med Pediatr Oncol. 1992;20(2):105-13 [1734214.001]
  • [Cites] Cancer Surv. 1997;30:59-75 [9547986.001]
  • [Cites] J Clin Pathol. 2003 Mar;56(3):188-92 [12610094.001]
  • [Cites] Cancer Invest. 2004;22(2):304-11 [15199612.001]
  • [Cites] Eur J Nucl Med Mol Imaging. 2002 Sep;29(9):1155-65 [12192560.001]
  • [Cites] Am J Clin Pathol. 2004 Apr;121(4):496-506 [15080301.001]
  • [Cites] N Engl J Med. 1996 May 9;334(19):1238-48 [8606720.001]
  • [Cites] Blood. 2001 Jun 1;97(11):3370-9 [11369626.001]
  • [Cites] J Natl Cancer Inst Monogr. 1998;(23):95-100 [9709310.001]
  • [Cites] J Pediatr. 1994 Dec;125(6 Pt 1):876-85 [7996359.001]
  • [Cites] Curr Med Chem. 2006;13(26):3165-89 [17168705.001]
  • [Cites] Br J Haematol. 2004 May;125(3):414-5 [15086431.001]
  • [Cites] Exp Hematol. 2003 Apr;31(4):309-15 [12691918.001]
  • [Cites] Pediatr Blood Cancer. 2010 Feb;54(2):307-10 [19856388.001]
  • [Cites] Pediatr Blood Cancer. 2005 Nov;45(6):753-69 [15929129.001]
  • [Cites] Blood. 1999 Nov 15;94(10):3294-306 [10552938.001]
  • [Cites] Med Pediatr Oncol. 2000 Jul;35(1):20-7 [10881003.001]
  • [Cites] J Clin Oncol. 1998 May;16(5):1729-35 [9586885.001]
  • [Cites] Cancer Res. 2001 May 1;61(9):3535-40 [11325813.001]
  • [Cites] J Clin Oncol. 2000 Nov 15;18(22):3845-53 [11078498.001]
  • [Cites] Eur J Cancer. 2005 Nov;41(16):2485-501 [16243519.001]
  • [Cites] J Pediatr Hematol Oncol. 2009 Dec;31(12):936-41 [19875969.001]
  • [Cites] Ann Nucl Med. 2002 Jul;16(5):337-45 [12230093.001]
  • [Cites] J Clin Invest. 1999 Jul;104(2):155-62 [10411544.001]
  • [Cites] Blood. 1998 Nov 15;92(10):3591-8 [9808552.001]
  • [Cites] JAMA. 2000 Jul 12;284(2):205-9 [10889594.001]
  • [Cites] Leuk Lymphoma. 2005 Oct;46(10):1489-96 [16194895.001]
  • [Cites] Leukemia. 2004 Feb;18(2):238-42 [14628072.001]
  • [Cites] Proc Natl Acad Sci U S A. 2009 Jun 9;106(23):9414-8 [19470474.001]
  • [Cites] Blood. 2000 Dec 15;96(13):4319-27 [11110708.001]
  • [Cites] Am J Hematol. 2003 Jan;72(1):53-63 [12508269.001]
  • [Cites] Clin Cancer Res. 2004 May 15;10(10):3371-6 [15161691.001]
  • [Cites] Clin Cancer Res. 2006 Sep 15;12(18):5329-35 [17000665.001]
  • [Cites] J Pediatr Hematol Oncol. 1998 Jul-Aug;20(4):282-96 [9702999.001]
  • [Cites] Pediatr Blood Cancer. 2008 Jan;50(1):37-45 [17420992.001]
  • [Cites] N Engl J Med. 2002 Jan 24;346(4):235-42 [11807147.001]
  • [Cites] Cancer. 2003 Sep 15;98(6):1283-91 [12973853.001]
  • [Cites] N Engl J Med. 1997 Oct 30;337(18):1259-66 [9345074.001]
  • [Cites] J Clin Oncol. 2001 Jan 15;19(2):414-9 [11208833.001]
  • [Cites] Blood. 2001 Jun 15;97(12):3699-706 [11389005.001]
  • [Cites] Br J Haematol. 2003 Feb;120(4):660-70 [12588354.001]
  • [Cites] Cancer. 2005 Nov 15;104(10):2133-40 [16211546.001]
  • (PMID = 20640605.001).
  • [ISSN] 1558-822X
  • [Journal-full-title] Current hematologic malignancy reports
  • [ISO-abbreviation] Curr Hematol Malig Rep
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Cysteine Proteinase Inhibitors; 0 / Histone Deacetylase Inhibitors; 0 / Protein Kinase Inhibitors; 0 / TNF-Related Apoptosis-Inducing Ligand; EC 2.4.2.1 / Purine-Nucleoside Phosphorylase
  •  go-up   go-down


9. Vieira Pinheiro JP, Lanversa C, Würthwein G, Beier R, Casimiro da Palma J, von Stackelberg A, Boos J: Drug monitoring of PEG-asparaginase treatment in childhood acute lymphoblastic leukemia and non-Hodgkin's lymphoma. Leuk Lymphoma; 2002 Oct;43(10):1911-20
Genetic Alliance. consumer health - Lymphoblastic lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Drug monitoring of PEG-asparaginase treatment in childhood acute lymphoblastic leukemia and non-Hodgkin's lymphoma.
  • This is an updated review of the pharmacokinetic profile of PEG-asparaginase (PEG-ASNase) in childhood acute lymphoblastic leukemia (ALL) or non-Hodgkin's lymphoma (NHL).
  • In a total of 271 children undergoing ALL/NHL or relapsed ALL treatment according to the Berlin-Frankfurt-Münster (BFM) protocols, drug monitoring of ASNase serum activity was performed after PEG-ASNase infusions.
  • Large interpatient variability was seen at each dose level resulting in a relevant number of patients not achieving adequate treatment intensity.
  • Neither the extent of ASNase pre-treatment nor a prior event of a hypersensitivity reaction against unmodified ASNase had any impact on PEG-ASNase pharmacokinetics.
  • It is concluded that escalation of the dose of PEG-ASNase did not result in a significant prolongation of time with activity values considered therapeutic.
  • Drug monitoring is advisable for early detection of patients with rapid elimination in order to ensure maximum treatment intensity.
  • [MeSH-major] Asparaginase / pharmacokinetics. Drug Monitoring. Lymphoma, Non-Hodgkin / drug therapy. Polyethylene Glycols / pharmacokinetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy
  • [MeSH-minor] Adolescent. Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Child. Child, Preschool. Dose-Response Relationship, Drug. Drug Hypersensitivity. Female. Humans. Infant. Male. Reproducibility of Results. Retrospective Studies


10. Seidemann K, Henze G, Beck JD, Sauerbrey A, Kühl J, Mann G, Reiter A: Non-Hodgkin's lymphoma in pediatric patients with chromosomal breakage syndromes (AT and NBS): experience from the BFM trials. Ann Oncol; 2000;11 Suppl 1:141-5
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Non-Hodgkin's lymphoma in pediatric patients with chromosomal breakage syndromes (AT and NBS): experience from the BFM trials.
  • BACKGROUND: Lymphoma and leukemia are the commonest malignant diseases in patients with chromosomal breakage syndromes and immunodeficiency (Ataxia teleangiectasia (AT) and Nijmegen breakage syndrome (NBS)).
  • With improved management of infections, malignant disease is more frequently diagnosed and has become one of the commonest causes of death in pediatric AT and NBS.
  • PATIENTS AND METHODS: In three consecutive multicenter therapy trials for pediatric non-Hodgkin's lymphoma (NHL) (NHL-BFM), 1569 patients with newly diagnosed NHL have been registered between 1986 and 1997.
  • RESULTS: Median age of patients with AT and NBS at diagnosis of NHL was nine years.
  • NHL-entities differed from non-AT/NBS-patients: diffuse large B-cell lymphomas, n = 7 (78%); ALCL, n = 1; lymphoblastic T-cell lymphoma, n = 1.
  • CONCLUSIONS: Patients with AT and NBS suffer from rare entities of pediatric NHL.
  • Curative treatment is possible and should be attempted.
  • Intensity of therapy should be adjusted to individual risk factors and tolerance.

  • MedlinePlus Health Information. consumer health - Ataxia Telangiectasia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10707797.001).
  • [ISSN] 0923-7534
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Clinical Trial; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


11. Pillon M, Piglione M, Garaventa A, Conter V, Giuliano M, Arcamone G, Mura R, Cellini M, D'Amore ES, Varotto S, Mussolin L, Rosolen A, AIEOP-NHL Committee: Long-term results of AIEOP LNH-92 protocol for the treatment of pediatric lymphoblastic lymphoma: a report of the Italian Association of Pediatric Hematology and Oncology. Pediatr Blood Cancer; 2009 Dec;53(6):953-9
Genetic Alliance. consumer health - Lymphoblastic lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term results of AIEOP LNH-92 protocol for the treatment of pediatric lymphoblastic lymphoma: a report of the Italian Association of Pediatric Hematology and Oncology.
  • BACKGROUND: Lymphoblastic lymphoma (LBL) is the second most frequent lymphoma subtype in childhood.
  • It is commonly treated according to therapy strategies for lymphoblastic leukemia.
  • METHODS: The AIEOP LNH-92 protocol was a modified LSA2-L2 therapy used for both T- and B-cell precursor LBL and included Induction, Consolidation, and Maintenance treatment with a total duration of 11 and 24 months for stages I and II, stages III and IV disease, respectively.
  • Outcome was comparable to most concomitant international protocols for LBL, but inferior to recent trials that included reinduction treatment or a higher intensity therapy for high stage disease.
  • Nevertheless, an intensified treatment is warranted for high stage disease.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy
  • [MeSH-minor] Adolescent. Child. Child, Preschool. Drug-Induced Liver Injury. Female. Hematologic Diseases / chemically induced. Humans. Infant. Male. Remission Induction. Survival Analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Pediatr Blood Cancer. 2009 Dec;53(6):917-9 [19672977.001]
  • (PMID = 19621432.001).
  • [ISSN] 1545-5017
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


12. Dalle JH, Mechinaud F, Michon J, Gentet JC, de Lumley L, Rubie H, Schmitt C, Patte C: Testicular disease in childhood B-cell non-Hodgkin's lymphoma: the French Society of Pediatric Oncology experience. J Clin Oncol; 2001 May 01;19(9):2397-403
MedlinePlus Health Information. consumer health - Testicular Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Testicular disease in childhood B-cell non-Hodgkin's lymphoma: the French Society of Pediatric Oncology experience.
  • PURPOSE: To investigate whether testicular disease in childhood B-cell lymphoma should continue to be considered a sanctuary site, as it is with other lymphoid malignancies such as acute lymphoblastic leukemia.
  • PATIENTS AND METHODS: Seven hundred forty-two children with B-cell non-Hodgkin's lymphoma were included in the LMB protocols of the French Society of Pediatric Oncology from February 1981 to May 1994.
  • We describe the clinical presentation and outcome of these 30 patients, who were treated without local radiation therapy.
  • The median patient age was 8.5 years (range, 2 to 14 years), and their cancers were stage III (18 patients), stage IV (five patients), and B-cell acute lymphoblastic leukemia (seven patients).
  • CONCLUSION: Testicular disease does not seem to confer a poor prognosis, and it is curable with intensive combination chemotherapy alone.
  • Local treatment (surgery or radiation) is avoidable; therefore, gonadal function can be preserved.
  • [MeSH-major] Lymphoma, B-Cell / therapy. Testicular Neoplasms / therapy
  • [MeSH-minor] Adolescent. Child. Child, Preschool. Combined Modality Therapy. Humans. Male. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11331318.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


13. Won SC, Han JW, Kwon SY, Shin HY, Ahn HS, Hwang TJ, Yang WI, Lyu CJ: Autologous peripheral blood stem cell transplantation in children with non-Hodgkin's lymphoma: A report from the Korean society of pediatric hematology-oncology. Ann Hematol; 2006 Nov;85(11):787-94
Genetic Alliance. consumer health - Transplantation.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Autologous peripheral blood stem cell transplantation in children with non-Hodgkin's lymphoma: A report from the Korean society of pediatric hematology-oncology.
  • Recent development of stratified chemotherapeutic regimens has rapidly improved the survival rate of non-Hodgkin's lymphoma (NHL) of childhood.
  • Despite these improvements, the outcome for children with recurrent or refractory NHL remains dismal.
  • We explored the use of high-dose chemotherapy followed by autologous peripheral blood stem cell transplantation (HDC/PBSCT) for children with either refractory or recurrent NHL, and we evaluated various factors influencing outcome of HDC/PBSCT.
  • All patients had refractory or recurrent NHL.
  • Sex, stage at diagnosis, histologic subtype (lymphoblastic, Burkitt's, and large-cell lymphoma), LDH level at diagnosis, disease status at transplantation, and preparative regimens for HDC/PBSCT were explored.
  • In regard to the patients, six had Burkitt's lymphoma, 13 had lymphoblastic lymphoma, and 14 had large-cell lymphoma.
  • The EFS for Burkitt's, lymphoblastic, and large-cell lymphoma was 66.7+/-27.2, 50.5+/-14.8, and 82.1+/-11.7%, respectively.
  • In comparison with lymphoblastic and non-lymphoblastic lymphoma, the relative risk for lymphoblastic lymphoma was higher than the others (P = 0.037).
  • EFS between anaplastic large-cell and diffuse large-cell lymphoma was 100 and 55.6+/-24.9%, respectively (P = 0.106).
  • Status at transplantation was the most predictive factor for the survival after HDC/PBSCT (EFS for CR 70.8+/-9.5% vs non-CR 20.0+/-17.9%, P = 0.008).
  • HDC/PBSCT is considered applicable to recurrent or refractory pediatric NHL patients safely and it could replace conventional chemotherapy.
  • In this study, children with CR status at the time of HDC/PBSCT showed higher survival rate.
  • However, refractory or recurrent lymphoblastic lymphoma patients showed dismal results.
  • Therefore, new therapeutic modalities may be needed for this group of NHL patients.
  • [MeSH-major] Lymphoma, Non-Hodgkin / therapy. Peripheral Blood Stem Cell Transplantation
  • [MeSH-minor] Adolescent. Child. Child, Preschool. Female. Humans. Infant. Korea. Male. Retrospective Studies. Salvage Therapy. Survival. Survival Analysis. Transplantation, Autologous. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Ann Hematol. 2007 Apr;86(4):309
  • (PMID = 16932891.001).
  • [ISSN] 0939-5555
  • [Journal-full-title] Annals of hematology
  • [ISO-abbreviation] Ann. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


14. Neth O, Seidemann K, Jansen P, Mann G, Tiemann M, Ludwig WD, Riehm H, Reiter A: Precursor B-cell lymphoblastic lymphoma in childhood and adolescence: clinical features, treatment, and results in trials NHL-BFM 86 and 90. Med Pediatr Oncol; 2000 Jul;35(1):20-7
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Precursor B-cell lymphoblastic lymphoma in childhood and adolescence: clinical features, treatment, and results in trials NHL-BFM 86 and 90.
  • BACKGROUND: Precursor B-cell lymphoblastic lymphoma (PBLL) is a rare subtype of childhood non-Hodgkin lymphoma (NHL).
  • The purpose of our study was to investigate frequency and clinicopathological features of PBLL in children and to test prospectively the efficacy of an ALL-type therapy for treatment of these patients.
  • PROCEDURE: From October, 1986, to March, 1995, 1,075 patients up to 18 years of age suffering from all kinds of NHL were registered in the two consecutive multicenter studies NHL-BFM 86 and 90.
  • Twenty-one PBLL patients were treated according to a BFM-ALL-type protocol: an eight-drug induction over 9 weeks was followed by an 8-week consolidation including methotrexate 5 g/m(2) x4.
  • Patients in stages I and II continued with maintenance up to a total therapy duration of 24 months, whereas patients in stages III and IV received an additional eight-drug intensification and cranial radiotherapy (12 Gy for prophylaxis) after consolidation.
  • Six PBLL patients were treated according to the BFM-protocol for B-NHL, stratified according to stage and tumor load and consisiting of two to six 5-day courses of chemotherapy.
  • With a median follow-up time of 4.
  • 25 years, the estimated probability for event-free survival (pEFS) at 10 years for the total group was 0.73 (SE 0.10).
  • Five patients (2, 1, 1, and 1 patients at stages I, II, III, and IV, respectively) relapsed: 2 of 21 patients who were treated according to the ALL strategy and 3 of 6 who were treated according to the B-NHL-protocol.
  • CONCLUSIONS: PBLL accounts for 2.5% of childhood NHL.
  • An ALL-type therapy strategy appears to be superior to a short-pulse B-NHL protocol.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / mortality

  • Genetic Alliance. consumer health - Lymphoblastic lymphoma.
  • Hazardous Substances Data Bank. DAUNORUBICIN .
  • Hazardous Substances Data Bank. PREDNISONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2000 Wiley-Liss, Inc.
  • (PMID = 10881003.001).
  • [ISSN] 0098-1532
  • [Journal-full-title] Medical and pediatric oncology
  • [ISO-abbreviation] Med. Pediatr. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] UNITED STATES
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; EC 3.5.1.1 / Asparaginase; VB0R961HZT / Prednisone; ZS7284E0ZP / Daunorubicin; PVDA protocol
  •  go-up   go-down


15. Bryant ML, Worthington MA, Parsons K: Treatment of osteoporosis/osteopenia in pediatric leukemia and lymphoma. Ann Pharmacother; 2009 Apr;43(4):714-20
MedlinePlus Health Information. consumer health - Osteoporosis.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of osteoporosis/osteopenia in pediatric leukemia and lymphoma.
  • OBJECTIVE: To evaluate the efficacy and safety of various treatment options for osteopenia and osteoporosis secondary to cancer treatment in pediatric patients undergoing cancer therapy.
  • DATA SOURCES: A systematic search of PubMed (1949-November 2008) and International Pharmaceutical Abstracts (to November 2008) was conducted using the following search terms: osteoporosis, osteopenia, pediatrics, cancer, neoplasms, chemotherapy, bisphosphonates, calcium, vitamin D, calcitonin, and physical therapy.
  • STUDY SELECTION AND DATA EXTRACTION: All prospective studies that evaluated various osteoporosis treatment options in pediatric patients undergoing chemotherapy were included.
  • Results from studies evaluating bisphosphonates and other treatments in children with osteoporosis due to other causes were also included if important safety and efficacy data were provided.
  • Most commonly reported primary efficacy endpoints included comparisons of bone density parameters measured before and after treatment.
  • DATA SYNTHESIS: Four clinical studies and 2 case reports describing treatment with bisphosphonates, specifically alendronate and pamidronate, for osteoporosis or osteopenia in pediatric cancer patients were identified.
  • Results from the trials showed that these medications were efficacious in reducing bone mineral density loss during cancer therapy and were well tolerated in this special population.
  • Four additional clinical trials involving the treatment of osteoporosis or osteopenia in children and adolescents who developed bone degeneration after chronic steroid therapy are also included.
  • In these trials, treatment options such as calcitonin, and calcium and vitamin D supplementation were also shown to be beneficial.
  • CONCLUSIONS: The clinical trials published to date are limited to only a few conducted in small populations of patients diagnosed with lymphoblastic leukemia or non-Hodgkin's lymphoma.
  • [MeSH-major] Bone Diseases, Metabolic / therapy. Leukemia / therapy. Lymphoma / therapy. Osteoporosis / therapy
  • [MeSH-minor] Antineoplastic Agents / therapeutic use. Child. Clinical Trials as Topic / methods. Humans. Treatment Outcome

  • Genetic Alliance. consumer health - Osteoporosis.
  • MedlinePlus Health Information. consumer health - Leukemia.
  • MedlinePlus Health Information. consumer health - Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19336653.001).
  • [ISSN] 1542-6270
  • [Journal-full-title] The Annals of pharmacotherapy
  • [ISO-abbreviation] Ann Pharmacother
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 19
  •  go-up   go-down


16. Laver JH, Mahmoud H, Pick TE, Hutchison RE, Weinstein HJ, Schwenn M, Weitzman S, Murphy SB, Ochoa S, Shuster JJ: Results of a randomized phase III trial in children and adolescents with advanced stage diffuse large cell non-Hodgkin's lymphoma: a Pediatric Oncology Group study. Leuk Lymphoma; 2002 Jan;43(1):105-9
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Results of a randomized phase III trial in children and adolescents with advanced stage diffuse large cell non-Hodgkin's lymphoma: a Pediatric Oncology Group study.
  • PURPOSE: The Pediatric Oncology Group (POG) adopted a histology-based approach to the management of pediatric non-Hodgkin's lymphomas (NHL) utilizing the National Cancer Institute Working Formulation for Clinical Usage.
  • Patients with diffuse large cell lymphoma (DLCL) were treated on a separate protocol from small cell diffuse undifferentiated or lymphoblastic lymphomas.
  • PATIENTS AND METHODS: One hundred and twenty eligible stage III or IV NHL patients with the confirmed diagnosis of diffuse large cell or immunoblastic histology were enrolled on study between October 1986 and November 1991.
  • In both treatment programs methotrexate was substituted when the doxorubicin cumulative dose reached 450 mg/m2.
  • Radiation was administered to bulky disease if progression or no response were observed after induction therapy.
  • Planned duration of therapy was 12 months.
  • While there was no statistically significant difference between the two treatment arms (p = 0.28), we can only say that we are 95% confident that the difference in 5-year EFS falls in the wide range from 28% in favor of APO to 8% favoring ACOP+.
  • Ten patients received radiation therapy to achieve remission.
  • CONCLUSION: The efficacy of elimination of cyclophosphamide from the treatment program of children and adolescents with advanced stage diffuse large cell lymphoma was inconclusive as to its effect on EFS.
  • Furthermore, the majority of the patients (92%) did not require any radiation therapy to bulky disease indicating that the chemotherapy regimens are quite efficient for achievement of complete remission.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cyclophosphamide / therapeutic use. Lymphoma, Large B-Cell, Diffuse / drug therapy
  • [MeSH-minor] 6-Mercaptopurine / administration & dosage. Adolescent. Child. Disease-Free Survival. Doxorubicin / administration & dosage. Female. Humans. Male. Prednisone / administration & dosage. Prospective Studies. Recurrence. Remission Induction / methods. Survival Rate. Treatment Outcome. Vincristine / administration & dosage

  • Genetic Alliance. consumer health - Lymphoma, large-cell.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. MERCAPTOPURINE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11908712.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA03161; United States / NCI NIH HHS / CA / CA05587; United States / NCI NIH HHS / CA / CA11233; United States / NCI NIH HHS / CA / CA15089; United States / NCI NIH HHS / CA / CA20549; United States / NCI NIH HHS / CA / CA25408; United States / NCI NIH HHS / CA / CA28383; United States / NCI NIH HHS / CA / CA28476; United States / NCI NIH HHS / CA / CA29139; United States / NCI NIH HHS / CA / CA30696; United States / NCI NIH HHS / CA / CA32053; United States / NCI NIH HHS / CA / CA33603; United States / NCI NIH HHS / CA / CA35587; United States / NCI NIH HHS / CA / CA69177; United States / NCI NIH HHS / CA / CA69428
  • [Publication-type] Clinical Trial; Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; E7WED276I5 / 6-Mercaptopurine; VB0R961HZT / Prednisone; ACOP protocol 2
  •  go-up   go-down


17. Laver JH, Mahmoud H, Pick TE, Hutchinson RE, Weinstein HJ, Schwenn M, Weitzman S, Murphy SB, Ochoa S, Shuster JJ, Pediatric Oncology Group: Results of a randomized phase III trial in children and adolescents with advanced stage diffuse large cell non Hodgkin's lymphoma: a Pediatric Oncology Group study. Leuk Lymphoma; 2001 Jul;42(3):399-405
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Results of a randomized phase III trial in children and adolescents with advanced stage diffuse large cell non Hodgkin's lymphoma: a Pediatric Oncology Group study.
  • The Pediatric Oncology Group (POG) adopted a histology-based approach to the management of pediatric non-Hodgkin's lymphomas (NHL) utilizing the National Cancer Institute Working Formulation for Clinical Usage.
  • Patients with diffuse large cell lymphoma (DLCL) were treated on a separate protocol from small cell diffuse undifferentiated or lymphoblastic lymphomas.
  • One hundred and twenty eligible stage III or IV NHL patients with the confirmed diagnosis of diffuse large cell or immunoblastic histology were enrolled on study between October 1986 and November 1991.
  • In both treatment programs methotrexate was substituted when the doxorubicin cumulative dose reached 450 mg/m2.
  • Radiation was administered to bulky disease if progression or no response were observed after induction therapy.
  • Planned duration of therapy was 12 months.
  • While there was no statistically significant difference between the two treatment arms (p = 0.28), we can only say that we are 95% confident that the difference in 5-year EFS falls in the wide range from 28% in favor of APO to 8% favoring ACOP+.
  • Ten patients received radiation therapy to achieve.
  • In conclusion the efficacy of elimination of cyclophosphamide from the treatment program of children and adolescents with advanced stage diffuse large cell lymphoma was inconclusive as to its effect on EFS.
  • Furthermore, the majority of the patients (92%) did not require any radiation therapy to bulky disease indicating that the chemotherapy regimens are quite efficient for achievement of complete remission.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, Large B-Cell, Diffuse / drug therapy
  • [MeSH-minor] Adolescent. Antigens, CD / analysis. Child. Continental Population Groups. Cyclophosphamide / administration & dosage. Disease-Free Survival. Doxorubicin / administration & dosage. Humans. Immunohistochemistry. Neoplasm Metastasis. Prednisolone / administration & dosage. Prednisone / administration & dosage. Remission Induction. Time Factors. United States. Vincristine / administration & dosage

  • Genetic Alliance. consumer health - Lymphoma, large-cell.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISOLONE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11699405.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Antigens, CD; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; 9PHQ9Y1OLM / Prednisolone; VB0R961HZT / Prednisone; VAP-cyclo protocol; VPD protocol
  •  go-up   go-down


18. Duzova A, Cetin M, Gümrük F, Yetgin S: Acute tumour lysis syndrome following a single-dose corticosteroid in children with acute lymphoblastic leukaemia. Eur J Haematol; 2001 Jun;66(6):404-7
MedlinePlus Health Information. consumer health - Steroids.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Acute tumour lysis syndrome following a single-dose corticosteroid in children with acute lymphoblastic leukaemia.
  • Acute tumour lysis syndrome (ATLS) is a well recognised complication of treatment of a variety of malignant disorders.
  • It commonly occurs in patients with non-Hodgkin's lymphoma (NHL) and acute lymphoblastic leukaemia (ALL) with the administration of combined cytotoxic chemotherapy.
  • It is rarely reported after single-agent corticosteroid therapy.
  • We present two children with acute lymphoblastic leukaemia of T-cell lineage who developed acute tumour lysis syndrome after a single dose of prednisolone, and methylprednisolone at the beginning of the induction chemotherapy.
  • The second case was a 14-yr-old boy with ALL who developed ATLS following a single dose of methylprednisolone.
  • One should be aware of this potentially life-threatening complication especially while prescribing corticosteroids to patients with NHL and leukaemia.
  • [MeSH-major] Adrenal Cortex Hormones / adverse effects. Leukemia-Lymphoma, Adult T-Cell / drug therapy. Tumor Lysis Syndrome / etiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11488940.001).
  • [ISSN] 0902-4441
  • [Journal-full-title] European journal of haematology
  • [ISO-abbreviation] Eur. J. Haematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Adrenal Cortex Hormones
  • [Number-of-references] 20
  •  go-up   go-down


19. Burkhardt B, Woessmann W, Zimmermann M, Kontny U, Vormoor J, Doerffel W, Mann G, Henze G, Niggli F, Ludwig WD, Janssen D, Riehm H, Schrappe M, Reiter A: Impact of cranial radiotherapy on central nervous system prophylaxis in children and adolescents with central nervous system-negative stage III or IV lymphoblastic lymphoma. J Clin Oncol; 2006 Jan 20;24(3):491-9
Hazardous Substances Data Bank. DAUNORUBICIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Impact of cranial radiotherapy on central nervous system prophylaxis in children and adolescents with central nervous system-negative stage III or IV lymphoblastic lymphoma.
  • PURPOSE: In the Non-Hodgkin's Lymphoma-Berlin-Frankfurt-Munster (NHL-BFM) 95 trial, we tested, against the historical control of the combined trials NHL-BFM90 and NHL-BFM86, whether prophylactic cranial radiotherapy (PCRT) can be omitted for CNS-negative patients with stage III or IV lymphoblastic lymphoma (LBL) with sufficient early response.
  • PATIENTS AND METHODS: Apart from the removal of PCRT in NHL-BFM95, the chemotherapy of the three trials was identical except for the amount of l-asparaginase and daunorubicin during induction.
  • The therapy in NHL-BFM95 was accepted to be noninferior when compared with trials NHL-BFM90/86 if the lower limit of the one-sided 95% CI for the difference in the 2-year probability of event-free-survival (pEFS) between target patients of NHL-BFM95 and the historical controls of NHL-BFM90/86 did not exceed -14%.
  • The target patient group consisted of stage III and IV patients who were CNS negative and responded well to induction therapy.
  • RESULTS: The number of target patients was 156 in NHL-BFM95 (median age, 8.6 years; range, 0.2 to 19.5 years) and 163 in NHL-BFM90/86 (median age, 8.4 years; range, 0.6 to 16.6 years).
  • For the target group, the pEFS rates at 2 and 5 years were 86% +/- 3% and 82% +/- 3%, respectively, in NHL-BFM95 (median follow-up time, 5.1 years; range, 2.1 to 9.1 years) compared with 91% +/- 2% and 88% +/- 3%, respectively in NHL-BFM90/86 (median follow-up time, 10.7 years; range, 5 to 15.4 years).
  • In NHL-BFM95, one isolated and two combined CNS relapses occurred compared with one combined CNS relapse in NHL-BFM90/86.
  • Five-year disease-free-survival rate was 88% +/- 3% in NHL-BFM95 compared with 91% +/- 2% in NHL-BFM90/86.
  • CONCLUSION: For CNS-negative patients with stage III or IV LBL and sufficient response to induction therapy, treatment without PCRT may be noninferior to treatment including PCRT.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Brain Neoplasms / prevention & control. Cranial Irradiation. Precursor Cell Lymphoblastic Leukemia-Lymphoma / pathology
  • [MeSH-minor] Adolescent. Asparaginase / administration & dosage. Child. Daunorubicin / administration & dosage. Disease-Free Survival. Female. Humans. Male. Neoplasm Staging. Remission Induction. Survival Analysis. Treatment Outcome

  • Genetic Alliance. consumer health - Lymphoblastic lymphoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16421426.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Controlled Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] EC 3.5.1.1 / Asparaginase; ZS7284E0ZP / Daunorubicin
  •  go-up   go-down


20. Burkhardt B, Reiter A, Landmann E, Lang P, Lassay L, Dickerhoff R, Lakomek M, Henze G, von Stackelberg A: Poor outcome for children and adolescents with progressive disease or relapse of lymphoblastic lymphoma: a report from the berlin-frankfurt-muenster group. J Clin Oncol; 2009 Jul 10;27(20):3363-9
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Poor outcome for children and adolescents with progressive disease or relapse of lymphoblastic lymphoma: a report from the berlin-frankfurt-muenster group.
  • PURPOSE: Little is known about the outcome of pediatric patients with lymphoblastic lymphoma (LBL) who suffer from progressive disease or relapse.
  • PATIENTS AND METHODS: We analyzed the pattern of LBL relapses after current non-Hodgkin's lymphoma Berlin-Frankfurt-Muenster (BFM) frontline therapy between April 1990 and March 2003.
  • Relapse therapy was according to acute lymphoblastic leukemia (ALL) -Relapse-BFM protocols or ALL-BFM protocols for high-risk patients.
  • RESULTS: Twenty-eight (11%) of 251 registered patients with precursor T-cell LBL (T-LBL) and six (8%) of 73 patients with precursor B-cell LBL (pB-LBL) suffered from relapse.
  • Of the 28 patients with T-LBL, one died from infection during relapse chemotherapy, 18 failed to achieve stable remission and died from disease progression, and nine reached allogeneic stem-cell transplantation (SCT).
  • These four patients are in second remission of their lymphoma for 48, 68, 125, and 131 months, respectively, after allogeneic SCT.
  • One of the four patients developed colon adenocarcinoma 47 months after SCT.
  • Of the six patients with pB-LBL who experienced relapse, one patient died as a result of toxicity of relapse chemotherapy, two died from disease progression after chemotherapy, and three received allogeneic SCT.
  • CONCLUSION: Using modern conventional therapy in the frontline treatment of LBL, 10% of patients suffer from progressive disease or relapse.
  • Because of the extremely poor reinduction success, the salvage rate for these patients is poor, with only a 14% (SE = 6%) overall survival.
  • [MeSH-major] Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy. Precursor T-Cell Lymphoblastic Leukemia-Lymphoma / therapy
  • [MeSH-minor] Adolescent. Analysis of Variance. Antineoplastic Combined Chemotherapy Protocols / adverse effects. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Child. Disease Progression. Female. Germany. Humans. Kaplan-Meier Estimate. Male. Multicenter Studies as Topic. Prognosis. Recurrence. Stem Cell Transplantation / adverse effects. Stem Cell Transplantation / methods. Switzerland. Transplantation, Homologous. Treatment Outcome. Young Adult

  • Genetic Alliance. consumer health - Lymphoblastic lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19433688.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


21. Yang CP, Hung JJ, Jaing TH, Lin KH, Lin DT, Lu MY, Liang DC, Chen SH, Liu HC, Hsiao CC, Shu SG, Chen JS, Chang TT, Chiou SS, Hsieh YL, Lin MT, Lee MT, Peng CT, Cheng SN, Chen RL, Chen BW, Lin KS: Treatment results of the TPOG-NHL92 protocols for childhood non-Hodgkin's lymphomas in Taiwan: a report from the Taiwan Pediatric Oncology Group (TPOG). Acta Paediatr Taiwan; 2000 Jul-Aug;41(4):193-204

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment results of the TPOG-NHL92 protocols for childhood non-Hodgkin's lymphomas in Taiwan: a report from the Taiwan Pediatric Oncology Group (TPOG)
  • A nation-wide chemotherapeutic trial for childhood non-Hodgkin's lymphoma (NHL) was conducted by the Taiwan Pediatric Oncology Group (TPOG).
  • Four TPOG-NHL92 protocols based on stage and histology were activated in 1992: TPOG-92LD (treatment duration: 8 months) was used for localized (stages I/II) NHL with any histology, 92LB (2 years), 92SNC (5 months), and 92LC (1 year) for advanced (stages III/IV) lymphoblastic (LB), small non-cleaved cell (SNC), and large cell (LC) lymphoma, respectively.
  • From January 1992 through June 1998, 200 children with newly diagnosed NHL from 13 member hospitals of TPOG were enrolled.
  • There were 54 (27.3%) patients with LB, 94 (47.5%) with SNC including B-cell acute lymphoblastic leukemia (B-ALL), and 50 (25.2%) with LC.
  • There were 176 patients eligible for evaluation of treatment results.
  • As of August 31, 1999, 26 patients relapsed, six died during remission, one patient developed secondary acute myelomonocytic leukemia, and 105 patients remained in continuous remission with a median remission duration of 49 months.
  • We concluded that following the strategy of stratification of therapy, only disease stages had prognostic significance in this study.
  • More efforts are needed to improve our treatment results.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, Non-Hodgkin / drug therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Acta Paediatr Taiwan. 2000 Jul-Aug;41(4):175-6 [11021000.001]
  • (PMID = 11021005.001).
  • [ISSN] 1608-8115
  • [Journal-full-title] Acta paediatrica Taiwanica = Taiwan er ke yi xue hui za zhi
  • [ISO-abbreviation] Acta Paediatr Taiwan
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China (Republic : 1949- )
  •  go-up   go-down


22. Gibbs IC, Tuamokumo N, Yock TI: Role of radiation therapy in pediatric cancer. Hematol Oncol Clin North Am; 2006 Apr;20(2):455-70
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Role of radiation therapy in pediatric cancer.
  • Whether in its preventive role of CNS prophylaxis for high-risk ALL, its central role in brain tumors, its adjunct role combined with chemotherapy for disease such as Hodgkin's lymphoma, Ewing's sarcoma, and rhabdomyosarcoma, or its palliative role for metastatic disease, radiation remains an important therapy for pediatric cancers.
  • [MeSH-minor] Adolescent. Brain Neoplasms / radiotherapy. Child. Hodgkin Disease / radiotherapy. Humans. Incidence. Lymphoma, Non-Hodgkin / radiotherapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / radiotherapy. Sarcoma / radiotherapy. United States / epidemiology

  • MedlinePlus Health Information. consumer health - Cancer in Children.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16730302.001).
  • [ISSN] 0889-8588
  • [Journal-full-title] Hematology/oncology clinics of North America
  • [ISO-abbreviation] Hematol. Oncol. Clin. North Am.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 78
  •  go-up   go-down


23. Alebouyeh M, Moussavi F, Haddad-Deylami H, Vossough P: Successful ambulatory treatment of Hodgkin's disease in Iranian children based on German-Austrian DAL-HD 85-90: single institutional results. Ann Oncol; 2005 Dec;16(12):1936-40
MedlinePlus Health Information. consumer health - Hodgkin Disease.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Successful ambulatory treatment of Hodgkin's disease in Iranian children based on German-Austrian DAL-HD 85-90: single institutional results.
  • BACKGROUND: Hodgkin's disease (HD) accounts for 7.5% of childhood malignancies in Iran.
  • In order to minimize chemotherapy toxicity and avoid eventual hospitalization and psychological and financial burdens we have applied since 1988, for the first time in Iran, a treatment regimen based on subsequently revised DAL-HD 85-90 and later GPOH-HD 95 protocols.
  • PATIENTS AND METHODS: During the period 1988-2004, 40 children with HD received DAL/GPOH-HD-adapted treatment; 25 males (62.5%) and 15 females (37.5%) (male/female ratio 1.7; age 4-14 years, mean 8.8).
  • Twenty nine patients (72.5%) received radiotherapy (20-25 Gy); four to the involved field (stage I), 25 to the upper mantel (stage II and also III with either residual or mediastinal mass) and three additionally to spleen and para-aortic lymph nodes.
  • Eleven patients received only chemotherapy.
  • Salvage chemotherapy consisted of MOPP/ABVD hybrid; six patients achieved a second sustained remission and three patients died: two due to relapse and progressive disease and the third one in CR, owing to thrombocytopenic hemorrhage and foudroyant pneumonia.
  • Aside from minor acute toxicities, three patients demonstrated azoospermia at the age of 18 years and one of these patients suffered non-Hodgkin lymphoma as a second malignancy.
  • HD occurred as a second malignancy in two patients with acute lymphoblastic leukemia.
  • Both received appropriate treatment and are over 10 years in CR.
  • CONCLUSIONS: The DAL/GPOH-HD-based treatment approach proved to achieve long-term sustained cure even in children with advanced HD disease.
  • The essentially outpatient diagnosis and treatment modus did not compromise the disease outcome, and was well tolerated and accepted by the patients and their parents.
  • The employed drugs are easily available and affordable.
  • This treatment approach is suitable for ambulatory use in developing countries.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16157620.001).
  • [ISSN] 0923-7534
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] England
  •  go-up   go-down


24. Kowalczyk J, Nurzyńska-Flak J, Armata J, Bogusławska-Jaworska J, Rokicka-Milewska R, Sońta-Jakimczyk D, Balwierz W, Chybicka A, Kaczmarek-Kanold M, Wachowiak J, Matysiak M, Pawelec K: Incidence and clinical characteristics of second malignant neoplasms in children: a multicenter study of a polish pediatric leukemia/lymphoma group. Med Sci Monit; 2004 Mar;10(3):CR117-22
MedlinePlus Health Information. consumer health - Leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Incidence and clinical characteristics of second malignant neoplasms in children: a multicenter study of a polish pediatric leukemia/lymphoma group.
  • BACKGROUND: The development of second malignant neoplasms (SMNs) in patients receiving chemotherapy and radiation therapy for primary cancers is one of the limitations to the quality and length of survival.
  • The present study was undertaken to examine various characteristics of children who developed SMNs following successful therapy for primary leukemia or Hodgkin's disease (HD).
  • MATERIAL/METHODS: A total of 3252 children with various forms of leukemia and 849 children with HD treated between, 1970-1997 at 7 pediatric centers of the Polish Pediatric Hematology/Oncology Group and subsequently followed-up entered the study.
  • RESULTS: Of the 3252 patients diagnosed as having acute leukemia during this period, 16 developed SMNs (estimated frequency 0.49%).
  • SMNs developed in 20 of the 849 children treated for HD (2.36%).
  • The most frequent SMNs were soft tissue sarcoma and thyroid carcinomas, mainly following Hodgkin's disease.
  • The interval from the end of initial treatment to diagnosis of an SMN ranged from 2 years 7 months to 17 years 6 months, with a median of 7 yrs 4 mo. for acute lymphoblastic leukemia (ALL) patients and 10 years for children with HD.
  • [MeSH-major] Hodgkin Disease / pathology. Hodgkin Disease / therapy. Leukemia / pathology. Leukemia / therapy. Neoplasms, Second Primary / diagnosis. Neoplasms, Second Primary / epidemiology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / pathology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy
  • [MeSH-minor] Adolescent. Child. Child, Preschool. Female. Follow-Up Studies. Humans. Incidence. Infant. Male. Sarcoma / secondary. Soft Tissue Neoplasms / secondary. Thyroid Neoplasms / secondary. Time Factors

  • MedlinePlus Health Information. consumer health - Childhood Leukemia.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14976453.001).
  • [ISSN] 1234-1010
  • [Journal-full-title] Medical science monitor : international medical journal of experimental and clinical research
  • [ISO-abbreviation] Med. Sci. Monit.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Poland
  •  go-up   go-down


25. von der Weid NX: Adult life after surviving lymphoma in childhood. Support Care Cancer; 2008 Apr;16(4):339-45
MedlinePlus Health Information. consumer health - Radiation Therapy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adult life after surviving lymphoma in childhood.
  • INTRODUCTION: Almost all pediatric lymphomas are malignant, high-grade tumors.
  • The combined incidence of Hodgkin's disease (HD) and non-Hodgkin lymphoma (NHL) reaches 10 to 12 new cases a year per million children under the age of 16 years, representing about 10% of all pediatric cancers.
  • HD makes up to 40% and NHL 60% of pediatric lymphomas.
  • During the last 20 years, cure rates raised dramatically so that currently over 90% of children and adolescents with HD and about 80% of those with NHL can be cured.
  • As cure can be achieved in a large majority of patients, long-term effects and quality of life of the survivors are nowadays the principal challenges to pediatric oncologists.
  • DISCUSSION: Like survivors from acute lymphoblastic leukemia, young adults cured from NHL may present with neurocognitive deficits, especially if treated at a young age and with cranial irradiation.
  • Intrathecal or high-dose intravenous chemotherapy with methotrexate may induce the same problems, although in a lesser extent and severity.
  • Radiation therapy to the neck and mediastinum (mantle field) induces a 50% risk of developing hypothyroidism and a 20% risk of developing thyroid nodules at 20 years.
  • The risk of thyroid cancer is 18 times higher the expected rate for the general population.
  • Cardiac toxicity can be enhanced by the concomitant therapy with adriamycin and lung toxicity by bleomycin.
  • Radiotherapy to the paraaortic and iliacal lymph nodes can affect gonadal function both in males and females; concomitant chemotherapy with alkylating agents like cyclophosphamide and especially procarbazine have a synergistic action and can lead to premature menopause as well as infertility.
  • Although the vast majority of survivors from pediatric lymphomas fare well, a minority present with extreme symptoms of depression and psychosomatic distress; female sex, low socio-economic status and treatment with intensive chemotherapy are important risk factors for a poor psychosocial outcome.
  • CONCLUSION: It is therefore crucial, but not always easy, to inform patients and families about potential late effects and organize follow-up after the pediatric age.
  • A well functioning network of pediatric oncologists, GP's, adult oncologists and other specialists of adult medicine must be developed in order to prevent, early detect and treat expected long-term toxicities.
  • [MeSH-major] Lymphoma. Radiotherapy / adverse effects. Survivors

  • MedlinePlus Health Information. consumer health - Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Leukemia. 1995 Dec;9(12):1990-6 [8609707.001]
  • [Cites] Cancer. 1976 Dec;38(6):2263-8 [826312.001]
  • [Cites] Lancet. 1999 Jul 3;354(9172):34-9 [10406363.001]
  • [Cites] N Engl J Med. 1981 Jun 4;304(23):1377-82 [7231460.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Oct 27;95(22):13176-81 [9789061.001]
  • [Cites] Cancer Treat Rep. 1982 Apr;66(4):977-89 [7074658.001]
  • [Cites] Pediatrics. 2002 Jul;110(1 Pt 1):42-52 [12093945.001]
  • [Cites] Med Pediatr Oncol. 2002 Apr;38(4):229-39 [11920786.001]
  • [Cites] J Natl Cancer Inst. 2001 Apr 18;93(8):618-29 [11309438.001]
  • [Cites] J Pediatr Hematol Oncol. 2005 Jan;27(1):28-36 [15654275.001]
  • [Cites] Med Pediatr Oncol. 1996 Aug;27(2):74-8 [8649323.001]
  • [Cites] J Clin Oncol. 2001 Jan 1;19(1):191-6 [11134212.001]
  • [Cites] J Clin Oncol. 2003 Apr 1;21(7):1359-65 [12663727.001]
  • [Cites] J Pediatr. 1993 Jul;123(1):59-64 [8320626.001]
  • [Cites] J Clin Oncol. 1991 Jan;9(1):145-51 [1985164.001]
  • [Cites] Med Pediatr Oncol. 1997 Jun;28(6):387-400 [9143382.001]
  • [Cites] Clin Cancer Res. 2000 Oct;6(10):4091-5 [11051261.001]
  • [Cites] Ann Neurol. 1999 Dec;46(6):834-41 [10589535.001]
  • [Cites] Pharmacogenetics. 2002 Nov;12(8):605-11 [12439220.001]
  • [Cites] Ann Oncol. 2002 Jun;13(6):819-29 [12123328.001]
  • [Cites] Blood. 1996 Apr 1;87(7):3045-52 [8639928.001]
  • [Cites] J Clin Oncol. 2006 Dec 20;24(36):5735-41 [17179107.001]
  • [Cites] N Engl J Med. 1988 Jan 14;318(2):76-81 [3336397.001]
  • [Cites] Cancer. 1981 May 15;47(10):2368-74 [6791800.001]
  • [Cites] J Clin Oncol. 1984 Jun;2(6):571-7 [6547167.001]
  • [Cites] Am J Obstet Gynecol. 1992 Mar;166(3):788-93 [1550144.001]
  • [Cites] J Clin Oncol. 1993 Jul;11(7):1208-15 [8315419.001]
  • [Cites] J Clin Oncol. 1999 Feb;17(2):569-77 [10080601.001]
  • [Cites] Swiss Med Wkly. 2001 Apr 7;131(13-14):180-7 [11345808.001]
  • [Cites] J Clin Oncol. 2000 Jun;18(12):2435-43 [10856104.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1990 Oct;19(4):873-80 [2211255.001]
  • [Cites] J Clin Endocrinol Metab. 2000 Sep;85(9):3227-32 [10999813.001]
  • [Cites] Br J Haematol. 2003 Aug;122(3):345-59 [12877662.001]
  • [Cites] Eur J Cancer. 2003 Feb;39(3):359-65 [12565989.001]
  • [Cites] J Pediatr. 1993 Oct;123(4):546-52 [8410505.001]
  • [Cites] JAMA. 1979 Oct 26;242(17):1877-81 [480620.001]
  • [Cites] Biochim Biophys Acta. 1998 Oct 1;1400(1-3):233-55 [9748598.001]
  • (PMID = 18196290.001).
  • [ISSN] 0941-4355
  • [Journal-full-title] Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer
  • [ISO-abbreviation] Support Care Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Germany
  • [Number-of-references] 41
  •  go-up   go-down


26. Ragusa R, Russo S, Villari L, Schilirò G: Hodgkin's disease as a second malignant neoplasm in childhood: report of a case and review of the literature. Pediatr Hematol Oncol; 2001 Sep;18(6):407-14
MedlinePlus Health Information. consumer health - Hodgkin Disease.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hodgkin's disease as a second malignant neoplasm in childhood: report of a case and review of the literature.
  • There is a known association between lymphoid malignancy and Hodgkin's disease (HD), but the development of HD in children who have been treated for leukemia or lymphoma is very uncommon.
  • Hodgkin's disease is, after retinoblastoma, the most common primary tumor that is associated with development of second malignant neoplasm.
  • We report the case of a eight-year-old girl who developed HD 6 years after treatment for common acute lymphoblastic leukemia (ALL).
  • This case prompted us to review the published literature for cases of secondary HD in childhood.
  • The most frequent causes of second tumors are radiotherapy, genetic susceptibility and prior treatment with certain chemotherapeutic agents, such as nitrogen mustards.
  • It is likely that any type of immunodeficiency, even without symptoms, might play a role in the development of second tumors in childhood.
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Disease-Free Survival. Female. Humans. Infant. Neoplasms, Second Primary / diagnosis. Neoplasms, Second Primary / etiology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Tomography, Emission-Computed, Single-Photon

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11554236.001).
  • [ISSN] 0888-0018
  • [Journal-full-title] Pediatric hematology and oncology
  • [ISO-abbreviation] Pediatr Hematol Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Number-of-references] 24
  •  go-up   go-down


27. Herrera L, Farah RA, Pellegrini VA, Aquino DB, Sandler ES, Buchanan GR, Vitetta ES: Immunotoxins against CD19 and CD22 are effective in killing precursor-B acute lymphoblastic leukemia cells in vitro. Leukemia; 2000 May;14(5):853-8
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunotoxins against CD19 and CD22 are effective in killing precursor-B acute lymphoblastic leukemia cells in vitro.
  • The potential impact of this form of therapy in pediatric precursor B-lineage acute lymphoblastic leukemia (pre-B ALL) has yet to be determined.
  • Mabs directed against the cell surface antigens, CD19 and CD22 conjugated to deglycosylated ricin A chain (dgRTA) have been tested in patients with non-Hodgkin's lymphoma (NHL), but not in patients with pre-B ALL.
  • Our results demonstrate that these ITs are specifically cytotoxic to primary pre-B ALL cells and that they should be further evaluated for the therapy of B-lineage ALL.
  • [MeSH-major] Antigens, CD / immunology. Antigens, CD19 / immunology. Antigens, Differentiation, B-Lymphocyte / immunology. Burkitt Lymphoma / immunology. Burkitt Lymphoma / pathology. Cell Adhesion Molecules. Immunotoxins / toxicity. Lectins. Preleukemia / pathology. Ricin / toxicity
  • [MeSH-minor] Adult. Antibody Specificity. Apoptosis / drug effects. Bone Marrow Cells / pathology. Cell Survival / drug effects. Child. Humans. Lymphocytes / drug effects. Lymphocytes / immunology. Lymphocytes / pathology. Sialic Acid Binding Ig-like Lectin 2. Stromal Cells / drug effects. Stromal Cells / pathology. Tumor Cells, Cultured

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Hazardous Substances Data Bank. RICIN .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10803517.001).
  • [ISSN] 0887-6924
  • [Journal-full-title] Leukemia
  • [ISO-abbreviation] Leukemia
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / T-32-CA09640
  • [Publication-type] Journal Article; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] ENGLAND
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Antigens, CD19; 0 / Antigens, Differentiation, B-Lymphocyte; 0 / CD22 protein, human; 0 / Cell Adhesion Molecules; 0 / Immunotoxins; 0 / Lectins; 0 / Sialic Acid Binding Ig-like Lectin 2; 9009-86-3 / Ricin
  •  go-up   go-down


28. Sun XF, Jiang WQ, Liu DG, Xia ZJ, Huang HQ, Zhang L, Li YH, Zhou ZM, Zhen ZJ, Xia Y, He YJ, Guan ZZ: [Efficacy of modified BFM-90 regimen on children and adolescents with T cell lymphoblastic lymphoma: a report of 20 cases]. Ai Zheng; 2004 Dec;23(12):1687-91
Hazardous Substances Data Bank. METHOTREXATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Efficacy of modified BFM-90 regimen on children and adolescents with T cell lymphoblastic lymphoma: a report of 20 cases].
  • BACKGROUND & OBJECTIVE: T-cell lymphoblastic lymphoma in childhood and adolescence is an aggressive malignant disease with higher mortality.
  • BFM-90 regimen for lymphoblastic lymphoma is one of the most effective regimens.
  • This study was designed to evaluate efficacy and toxicities of modified BFM-90 regimen on Chinese children and adolescents with lymphoblastic lymphoma.
  • METHODS: A total of 20 naive children and adolescents with T cell lymphoblastic lymphoma were enrolled, 7 in stage III, and 13 in stage IV.
  • All patients received modified BFM-90 regimen consisting of induction, consolidation and central nervous system prophylaxis, reinduced alleviation, and maintenance therapy.
  • Total treatment duration was 2 years.
  • Of 2 patients at CR1 received APBSC, 1 relapsed after transplantation, but achieved CR and survived after salvage chemotherapy;1 survived all along.
  • Of other patients achieved CR, 5 relapsed; of these 5 patients, 1 survived after allogeneic stem cell transplantation, 1 survived after autologous stem cell transplantation, 3 died of progressive disease after chemotherapy.
  • CONCLUSIONS: Modified BFM-90 regimen is feasible for Chinese children and adolescent patients with lymphoblastic lymphoma, and may improve survival rate of these patients.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy
  • [MeSH-minor] 6-Mercaptopurine / therapeutic use. Adolescent. Asparaginase / therapeutic use. Child. Child, Preschool. Cyclophosphamide / therapeutic use. Cytarabine / therapeutic use. Daunorubicin / therapeutic use. Female. Follow-Up Studies. Humans. Male. Methotrexate / therapeutic use. Neoplasm Recurrence, Local. Neoplasm Staging. Prednisone / therapeutic use. Remission Induction. Stem Cell Transplantation. Survival Rate. Treatment Outcome. Vincristine / therapeutic use

  • Genetic Alliance. consumer health - Lymphoblastic lymphoma.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. DAUNORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. MERCAPTOPURINE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15601561.001).
  • [Journal-full-title] Ai zheng = Aizheng = Chinese journal of cancer
  • [ISO-abbreviation] Ai Zheng
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 04079A1RDZ / Cytarabine; 5J49Q6B70F / Vincristine; 8N3DW7272P / Cyclophosphamide; E7WED276I5 / 6-Mercaptopurine; EC 3.5.1.1 / Asparaginase; VB0R961HZT / Prednisone; YL5FZ2Y5U1 / Methotrexate; ZS7284E0ZP / Daunorubicin; AIEOP acute lymphoblastic leukemia protocol
  •  go-up   go-down


29. Wössmann W, Schrappe M, Meyer U, Zimmermann M, Reiter A: Incidence of tumor lysis syndrome in children with advanced stage Burkitt's lymphoma/leukemia before and after introduction of prophylactic use of urate oxidase. Ann Hematol; 2003 Mar;82(3):160-5
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Incidence of tumor lysis syndrome in children with advanced stage Burkitt's lymphoma/leukemia before and after introduction of prophylactic use of urate oxidase.
  • To evaluate the clinical benefit of the prophylactic use of urate oxidase in children with non-Hodgkin's lymphoma (NHL), we analyzed the incidence and complications of tumor lysis syndrome (TLS) in children with B-cell acute lymphoblastic leukemia (B-ALL) or stage III/IV Burkitt's lymphoma and a lactate dehydrogenase (LDH) level > or =500 U/l before and after the introduction of a protocol amendment to use urate oxidase for the prophylaxis of TLS.
  • Data from 1791 children with NHL enrolled in the two subsequent multicenter studies NHL-BFM 90 and 95 were evaluated.
  • From November 1997 all children with B-ALL or stage III and IV B-NHL and LDH > or =500 U/l should receive urate oxidase prophylactically (period 3).
  • Initial chemotherapy was identical.
  • Altogether, 78 children (4.4%) developed a TLS.
  • Patients with B-ALL had the highest risk to develop a TLS (26.4%) followed by B-ALL/Burkitt's lymphoma and a LDH > or =500 U/l (14.9%).
  • In period 1, 16.1% and 9.2% of the latter children developed a TLS or anuria, respectively, compared to 12.3% and 6.2% in period 3 ( p=NS).
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / adverse effects. Burkitt Lymphoma / drug therapy. Tumor Lysis Syndrome / prevention & control. Urate Oxidase / therapeutic use

  • Genetic Alliance. consumer health - Burkitt's Lymphoma.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12634948.001).
  • [ISSN] 0939-5555
  • [Journal-full-title] Annals of hematology
  • [ISO-abbreviation] Ann. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] EC 1.1.1.27 / L-Lactate Dehydrogenase; EC 1.7.3.3 / Urate Oxidase
  •  go-up   go-down


30. Halperin EC, Laurie F, Fitzgerald TJ: An evaluation of the relationship between the quality of prophylactic cranial radiotherapy in childhood acute leukemia and institutional experience: a Quality Assurance Review Center-Pediatric Oncology Group study. Int J Radiat Oncol Biol Phys; 2002 Jul 15;53(4):1001-4
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] An evaluation of the relationship between the quality of prophylactic cranial radiotherapy in childhood acute leukemia and institutional experience: a Quality Assurance Review Center-Pediatric Oncology Group study.
  • PURPOSE: The Pediatric Oncology Group Protocol 9404 was a prospective clinical trial of two forms of chemotherapy in childhood T-cell acute lymphoblastic leukemia and advanced stage T-cell lymphoblastic non-Hodgkin's lymphoma.
  • The protocol called for prophylactic C1 whole brain external beam irradiation, 18 Gy in 2 Gy/fraction for 9 fractions.
  • Treatment volumes were scored as a minor deviation if the margins were less than specified or the fields were excessively large.
  • When the treating physician submitted a treatment plan and simulator film at the initiation of therapy to the Quality Assurance Review Center (QARC), a rapid turn-around review of the plan and suggestions for improvement was provided.
  • At the end of therapy, all simulator and port films were reviewed at the QARC.
  • The frequency of major deviations fell over time (1996-1997, 15.5% vs. 1998-2001, 4.7%, p < 0.001).
  • A trend (p < 0.09) was noted, however, for major deviations to decrease as a function of institutional experience, as well as over time (p < 0.001), supporting the validity of the hypothesis that pediatric clinical experience matters in QA for C1 whole brain leukemia radiotherapy.
  • [MeSH-major] Brain / radiation effects. Clinical Trials as Topic / standards. Precursor Cell Lymphoblastic Leukemia-Lymphoma / radiotherapy

  • MedlinePlus Health Information. consumer health - Clinical Trials.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12095569.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / 5U10CA15525-29; United States / NCI NIH HHS / CA / CA29511
  • [Publication-type] Clinical Trial; Controlled Clinical Trial; Journal Article; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  •  go-up   go-down


31. Xie XT, Jiang SY, Li BS, Yang LL: [Relationship between the expression of the genes encoding the key enzymes for cytarabine metabolism and the pharmacokinetics of cytarabine in the treatment of childhood acute leukemia with high-dose cytarabine]. Zhonghua Er Ke Za Zhi; 2008 Apr;46(4):276-80
Hazardous Substances Data Bank. CYTARABINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Relationship between the expression of the genes encoding the key enzymes for cytarabine metabolism and the pharmacokinetics of cytarabine in the treatment of childhood acute leukemia with high-dose cytarabine].
  • OBJECTIVE: It has been reported that high-dose cytarabine (HD-AraC) was very effective for childhood hematological malignancies, especially for improving the long-term survival of high-risk acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), and T-cell lymphoid malignancies (T-ALL, T-cell non-Hodgkin's lymphoma).
  • This study aimed to evaluate the pharmacokinetics of HD-AraC for childhood hematological malignancies, and the relationship between the expression of the genes coding the key enzymes for Ara-C metabolism with the outcome of the patients.
  • METHODS: The drug levels of Ara-C in plasma and cerebrospinal fluid were detected with HPLC while HD-AraC was used, the expression of deoxycytidine kinase (dCK) and cytidine deaminase (CDA) mRNA in human leukemia cell lines and the bone marrow cells were investigated in 48 cases of childhood hematological malignancies with RT-PCR methods, and the relationship between the expression of these enzymes mRNA and the outcome of the patients was analyzed. RESULTS:.
  • (1) When HD-AraC was used, the plasma levels of Ara-C and Ara-U could be respectively about 50 times and 25 times higher than those obtained when the patients were treated with regular dose of Ara-C treatment, and the level of Ara-C in cerebrospinal fluid could reach about 10% of plasma level of Ara-C. (2) There were significantly different expressions of dCK mRNA in different childhood acute leukemia (AL) patients, which were markedly related to the chemotherapy results.
  • There were no significant differences in expressions of dCK in T-ALL and B lineage ALL. (3) In vitro study found that the expressions of dCK and CDA mRNA did not change in leukemia cell lines incubated at different doses and times of Ara-C.
  • CONCLUSIONS: HD-AraC was a very effective protocol for childhood hematological malignancies for it could significantly elevate the plasma and cerebrospinal fluid drug levels.
  • Good long-term outcomes of the childhood T-ALL could be achieved as the B lineage ALL had been treated with HD-AraC regimen.
  • As the expression levels of dCK were much lower, it may be necessary for the treatment of AML with HD-AraC for consecutive three days.
  • [MeSH-minor] Child. Cytidine Deaminase / genetics. Deoxycytidine Kinase / genetics. Gene Expression. Humans. Leukemia, Myeloid, Acute / drug therapy. Leukemia, Myeloid, Acute / genetics. Leukemia, Myeloid, Acute / metabolism. Lymphoma, Non-Hodgkin / drug therapy. Lymphoma, Non-Hodgkin / genetics. Lymphoma, Non-Hodgkin / metabolism. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / metabolism

  • MedlinePlus Health Information. consumer health - Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19099730.001).
  • [ISSN] 0578-1310
  • [Journal-full-title] Zhonghua er ke za zhi = Chinese journal of pediatrics
  • [ISO-abbreviation] Zhonghua Er Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 04079A1RDZ / Cytarabine; EC 2.7.1.74 / Deoxycytidine Kinase; EC 3.5.4.5 / Cytidine Deaminase
  •  go-up   go-down


32. Vila L, Moreno L, Andrés MM, Fernández JM, Verdeguer A, Pérez-Valle S, Sangüesa C, Berbel O, Castel V: Could other viruses cause pediatric posttransplant lymphoproliferative disorder? Clin Transl Oncol; 2008 Jul;10(7):422-5
MedlinePlus Health Information. consumer health - Viral Infections.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Could other viruses cause pediatric posttransplant lymphoproliferative disorder?
  • We summarize the experience of our hospital, one of Spain's largest series of renal (294), liver (47) and allogeneic stem cell transplants (67), where four cases of PTLD have developed related to complex viral infections.
  • METHODS: Case 1 was a 24-month-old boy diagnosed with acute lymphoblastic leukemia who underwent allogeneic stem-cell transplantation (SCT).
  • He was seropositive for Epstein-Barr virus (EBV) and developed an aggressive Bcell non-Hodgkin's lymphoma (B-NHL) related to EBV reactivation and human herpesvirus 6 (HHV-6) infection.
  • Cases 2, 3, and 4 developed after kidney transplantation and were all EBV seronegative.
  • Current therapies include rituximab, decreasing immunosuppressive drugs. and conventional chemotherapy.

  • MedlinePlus Health Information. consumer health - After Surgery.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Pediatr Transplant. 2001 Aug;5(4):250-7 [11472603.001]
  • [Cites] Herpes. 2003 Dec;10(3):60-5 [14759337.001]
  • [Cites] Am J Transplant. 2004 Feb;4(2):222-30 [14974943.001]
  • [Cites] Blood. 2001 Aug 15;98(4):972-8 [11493441.001]
  • [Cites] J Infect Dis. 1997 Dec;176(6):1462-7 [9395355.001]
  • [Cites] Transplantation. 1999 Dec 27;68(12):1851-4 [10628763.001]
  • [Cites] Transpl Infect Dis. 2001 Jun;3(2):70-8 [11395972.001]
  • [Cites] Transplantation. 2001 Apr 27;71(8):1065-8 [11374404.001]
  • [Cites] Transplantation. 2002 Jan 15;73(1):100-4 [11792987.001]
  • (PMID = 18628071.001).
  • [ISSN] 1699-048X
  • [Journal-full-title] Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
  • [ISO-abbreviation] Clin Transl Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


33. Patte C, Sakiroglu O, Sommelet D: European experience in the treatment of hyperuricemia. Semin Hematol; 2001 Oct;38(4 Suppl 10):9-12

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] European experience in the treatment of hyperuricemia.
  • The nonrecombinant form of urate oxidase has been routinely used in France since 1975 as standard practice in the initial management of non-Hodgkin's lymphoma (NHL) and acute lymphoblastic leukemia (ALL), and for prevention of tumor lysis syndrome (TLS).
  • A retrospective study was performed to evaluate the frequency of metabolic complications and dialysis in 410 patients with B-cell stage III and IV NHL and L-3 ALL treated in France according to the LMB89 protocol, and to compare these results to those of other series of patients treated without urate oxidase.
  • Of the 57 patients treated at Institut Gustave-Roussy, only five had metabolic complications occurring in the first cycle of chemotherapy.
  • A recombinant form of urate oxidase (rasburicase) was therefore developed.
  • European clinical development results indicate that this agent produces a sharp and consistent decrease in uric acid levels in patients undergoing cytoreductive therapy.
  • Studies have demonstrated the efficacy of urate oxidase in lowering uric acid levels, preventing hyperuricemia after the initiation of cytoreductive therapy, and preserving renal function in patients with B-cell advanced stage NHL and ALL.
  • [MeSH-minor] Adolescent. Antineoplastic Agents / administration & dosage. Antineoplastic Agents / adverse effects. Antineoplastic Agents / toxicity. Child. Child, Preschool. Clinical Trials as Topic. Europe. Female. Humans. Leukemia, B-Cell / blood. Leukemia, B-Cell / complications. Leukemia, B-Cell / drug therapy. Lymphoma, B-Cell / blood. Lymphoma, B-Cell / complications. Lymphoma, B-Cell / drug therapy. Male. Retrospective Studies. Treatment Outcome. Tumor Lysis Syndrome / drug therapy. Tumor Lysis Syndrome / etiology. Tumor Lysis Syndrome / prevention & control. Urate Oxidase / therapeutic use

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2001 by W.B. Saunders Company.
  • (PMID = 11694946.001).
  • [ISSN] 0037-1963
  • [Journal-full-title] Seminars in hematology
  • [ISO-abbreviation] Semin. Hematol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 268B43MJ25 / Uric Acid; EC 1.7.3.3 / Urate Oxidase
  •  go-up   go-down


34. Kreitman RJ: Recombinant immunotoxins for the treatment of chemoresistant hematologic malignancies. Curr Pharm Des; 2009;15(23):2652-64
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Recombinant immunotoxins for the treatment of chemoresistant hematologic malignancies.
  • No agents of this class are approved yet for medical use, although a related molecule, denileukin diftitox, composed of interleukin-2 fused to truncated diphtheria toxin, is approved for relapsed/refractory cutaneous T-cell lymphoma.
  • Recombinant immunotoxins which have been tested in patients with chemotherapy-pretreated hematologic malignancies include LMB-2 (anti-CD25), BL22 (CAT-3888, anti-CD22) and HA22 (CAT-8015, anti-CD22), each containing an Fv fragment fused to truncated Pseudomonas exotoxin.
  • Major responses were observed with LMB-2 in adult T-cell leukemia, chronic lymphocytic leukemia (CLL), cutaneous T-cell lymphoma, Hodgkin's disease, and hairy cell leukemia (HCL).
  • HA22, an improved version of BL22 with higher affinity to CD22, is now undergoing phase I testing in HCL, CLL, non-Hodgkin's lymphoma, and pediatric acute lymphoblastic leukemia.
  • [MeSH-major] Drug Discovery / methods. Drug Resistance, Neoplasm / drug effects. Hematologic Neoplasms / drug therapy. Immunotoxins / therapeutic use. Recombinant Proteins / therapeutic use

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19689336.001).
  • [ISSN] 1873-4286
  • [Journal-full-title] Current pharmaceutical design
  • [ISO-abbreviation] Curr. Pharm. Des.
  • [Language] eng
  • [Grant] United States / Intramural NIH HHS / /
  • [Publication-type] Journal Article; Research Support, N.I.H., Intramural; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Diphtheria Toxin; 0 / Immunotoxins; 0 / Leukocidins; 0 / Pseudomonas aeruginosa Cytotoxins; 0 / Recombinant Proteins; 0 / Toxins, Biological
  • [Number-of-references] 190
  •  go-up   go-down


35. Mitsui T, Mori T, Fujita N, Inada H, Horibe K, Tsurusawa M, Lymphoma Committee, Japanese Pediatric Leukemia/Lymphoma Study Group: Retrospective analysis of relapsed or primary refractory childhood lymphoblastic lymphoma in Japan. Pediatr Blood Cancer; 2009 May;52(5):591-5
Genetic Alliance. consumer health - Lymphoblastic lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Retrospective analysis of relapsed or primary refractory childhood lymphoblastic lymphoma in Japan.
  • BACKGROUND AND PROCEDURE: To assess the clinical course with response to second-line treatment and to evaluate the role of hematopoietic stem cell transplantation (SCT) in children with relapsed or primary refractory lymphoblastic lymphoma (LBL), we analyzed data of 48 patients with relapsed/primary refractory diseases among 260 LBL patients identified in a national survey of 1996-2004.
  • Of 13 patients who showed progression despite first and second line therapy, only one patient was alive on the second relapse after unrelated cord blood transplantation.
  • Among 40 relapsed patients, the median time between initial diagnosis and relapse was 12.5 months (range 3-56 months).
  • Of all 48 patients, 3 were alive after chemotherapy alone.
  • Of the 33 patients, 14 were alive after high dose chemotherapy (HDC)/SCT.
  • With a 27.5-month median follow up period, the 3-year OS rate was 43.2 +/- 7.4% (estimate +/- SE).
  • [MeSH-major] Precursor Cell Lymphoblastic Leukemia-Lymphoma / epidemiology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / pathology
  • [MeSH-minor] Adolescent. Antineoplastic Agents / therapeutic use. Child. Child, Preschool. Disease Progression. Female. Humans. Infant. Japan / epidemiology. Male. Recurrence. Retrospective Studies. Survival Rate. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2009 Wiley-Liss, Inc.
  • (PMID = 19156862.001).
  • [ISSN] 1545-5017
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


36. Diagne I, Diagne-Gueye NR, Gaye-Ly K, Sow D, Camara B, Diack-Mbaye A, Signate-Sy H, Ba M, Sarr M, Moreira C, Kuakuvi N: [Management problems of malignant hemopathies among children in Senegal]. Dakar Med; 2002;47(1):12-7

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Problèmes posés par la prise en charge des hémopathies malignes chez l'enfant au Sénégal.
  • However they remain usually lethal instead of a great improvement of their prognosis in suitable therapeutic conditions.
  • The objective of this study was to determine the epidemiologic and evolutionnal profile of these pathologies, and identify practical management problems in a reference public pediatric service in Senegal.
  • The malignant type was acute leukemia (AL) in 11 cases (44%) including 9 cases of of acute lymphoblastic leukemia (ALL) and 2 cases of acute myeloblastic leukemia (AML); chronic myeloid leukemia (CML) in 2 cases (8%), Hodgkin's desease (HD) in 9 cases (36%) and non hodgkinian lymphoma (NHL) in 3 cases.
  • NHLwere Burkitt type in 2casesand lymphoblastic type in 1 case.
  • Their was no maxillary or facial localisation in Burkitt type lymphoma.
  • Among 19 patients whose records were available, 17 were subjected to chemotherapy.
  • However reference protocols were completely applyed in only 2 cases, one with HD and an other with lymphoblastic lymphoma.
  • Thirteen patients died while followed up and mean survival after first hospitalisation in these cases was 120 days in ALL, 38 days in AML, 2.5 years in HD and 18 months in NHL The other patients were lost of sight and presumed to be dead at home.
  • Eventually, this study showed that, in our hospital, children with malignant hemopathies did not derive benefit of therapeutic progress enregistered long time ago in developed countries, since they remain constantly lethal.
  • The main factors of lethality could be delayed transfer to hospital because of lack of knowledge about these pathologies in the peripheral health services and poor therapeutic conditions in reference hospitals.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15776584.001).
  • [ISSN] 0049-1101
  • [Journal-full-title] Dakar médical
  • [ISO-abbreviation] Dakar Med
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Senegal
  •  go-up   go-down


37. Sternberg A: Clofarabine. Bioenvision/ILEX. Curr Opin Investig Drugs; 2003 Dec;4(12):1479-87
MedlinePlus Health Information. consumer health - Cancer Chemotherapy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Clofarabine is a purine nucleoside antimetabolite under development by Bioenvision (under license from the Southern Research Institute) and ILEX for the potential treatment of solid tumors, acute myelogenous leukemia, non-Hodgkin's lymphoma, and acute lymphoblastic and chronic lymphocytic leukemia.
  • In September 2003, Bioenvision initiated a phase II trial in Europe in pediatric acute lymphoblastic leukemia, and in October 2003, ILEX submitted the first part of a rolling NDA to the FDA for the treatment of acute leukemia in children.
  • [MeSH-major] Arabinonucleosides / therapeutic use. Drugs, Investigational / therapeutic use. Neoplasms / drug therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14763136.001).
  • [ISSN] 1472-4472
  • [Journal-full-title] Current opinion in investigational drugs (London, England : 2000)
  • [ISO-abbreviation] Curr Opin Investig Drugs
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Adenine Nucleotides; 0 / Arabinonucleosides; 0 / Drugs, Investigational; 762RDY0Y2H / clofarabine
  • [Number-of-references] 64
  •  go-up   go-down


38. Gow KW, Lensing S, Hill DA, Krasin MJ, McCarville MB, Rai SN, Zacher M, Spunt SL, Strickland DK, Hudson MM: Thyroid carcinoma presenting in childhood or after treatment of childhood malignancies: An institutional experience and review of the literature. J Pediatr Surg; 2003 Nov;38(11):1574-80
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Thyroid carcinoma presenting in childhood or after treatment of childhood malignancies: An institutional experience and review of the literature.
  • METHODS: The authors reviewed the medical records of 8 children with PTM and 17 children with STM referred to St Jude Children's Research Hospital between February 1962 and February 2002 for evaluation and treatment of malignant thyroid carcinoma.
  • Seventeen patients had thyroid carcinoma as a second malignant neoplasm after treatment for acute lymphoblastic leukemia (n = 6), Hodgkin's disease (n = 5), central nervous system tumor (n = 2), Wilms' tumor (n = 1), retinoblastoma (n = 1), non-Hodgkin's lymphoma (n = 1), or neuroblastoma (n = 1).
  • Twelve of the 17 patients (70.6%) had received radiation to the thyroid gland during therapy for the primary cancer.
  • At the time of this report, all 17 patients are alive and in continue to be free of disease.
  • CONCLUSIONS: Pediatric thyroid carcinoma is uncommon and responds well to current therapy.
  • Given the limited period of follow-up of our cohort of secondary malignant thyroid tumors that arise after childhood cancer, these lesions appear to have similar presentations and outcomes when compared with primary carcinomas and can therefore be managed in the same manner.
  • [MeSH-minor] Adolescent. Adult. Child. Cohort Studies. Combined Modality Therapy. Female. Humans. Iodine Radioisotopes / therapeutic use. Lung Neoplasms / secondary. Lymphatic Metastasis. Male. Neoplasms / drug therapy. Neoplasms / radiotherapy. Neoplasms, Radiation-Induced / epidemiology. Retrospective Studies. Tennessee / epidemiology. Thyroidectomy. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14614703.001).
  • [ISSN] 1531-5037
  • [Journal-full-title] Journal of pediatric surgery
  • [ISO-abbreviation] J. Pediatr. Surg.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA 21765
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Iodine Radioisotopes
  • [Number-of-references] 49
  •  go-up   go-down


39. Abdullah S, Diezi M, Sung L, Dupuis LL, Geary D, Abla O: Sevelamer hydrochloride: a novel treatment of hyperphosphatemia associated with tumor lysis syndrome in children. Pediatr Blood Cancer; 2008 Jul;51(1):59-61

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sevelamer hydrochloride: a novel treatment of hyperphosphatemia associated with tumor lysis syndrome in children.
  • BACKGROUND: Sevelamer is a phosphate-binder used effectively for the treatment of hyperphosphatemia in patients treated with dialysis.
  • PROCEDURE: A retrospective chart review of all children with leukemia/lymphoma diagnosed between November 2002 and April 2004 who received sevelamer during their initial admission was conducted.
  • Nine children had acute lymphoblastic leukemia, one had acute myeloid leukemia and 3 had non-Hodgkin's lymphoma.
  • The median duration of sevelamer therapy was 2 days (range 1-7).
  • CONCLUSIONS: Sevelamer appears to be effective and tolerable for the treatment of hyperphosphatemia associated with tumor lysis syndrome.
  • [MeSH-major] Hyperphosphatemia / drug therapy. Polyamines / administration & dosage. Tumor Lysis Syndrome / complications
  • [MeSH-minor] Adolescent. Calcium Phosphates / blood. Chelating Agents / therapeutic use. Child. Child, Preschool. Female. Humans. Male. Phosphates / blood. Retrospective Studies. Sevelamer. Treatment Outcome. Vomiting / chemically induced

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2008 Wiley-Liss, Inc.
  • (PMID = 18240167.001).
  • [ISSN] 1545-5017
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Calcium Phosphates; 0 / Chelating Agents; 0 / Phosphates; 0 / Polyamines; 97Z1WI3NDX / calcium phosphate; 9YCX42I8IU / Sevelamer
  •  go-up   go-down






Advertisement